Sagard Capital Partners, L.P. (“Sagard Capital”) and IntegraMed America, Inc. (NASDAQ: INMD) (“IntegraMed”), a leader in developing, marketing and managing specialty healthcare facilities in the fertility and vein care markets, today announced the completion of Sagard Capital’s acquisition of IntegraMed for $14.05 per share in cash, representing a total equity purchase price of approximately $169.5 million. As a result of the transaction’s completion, IntegraMed’s common stock will cease trading at the close of market today and will be delisted from the NASDAQ Global Market. Dan Friedberg, Managing Partner of Sagard Capital, said, “We are thrilled to partner with IntegraMed and its impressive team of medical, clinical and administrative personnel. Over the past 25 years, they have built an enviable reputation for providing the highest levels of service to health care facilities that allow for superior patient care, treatment innovation and treatment financing solutions. Sagard is committed to providing IntegraMed’s physician practices, clinics and management with the resources necessary to deliver world-class patient care, to retain and grow top quality partners, and to develop complementary business opportunities. We see a significant opportunity to extend the reach of IntegraMed’s business, bringing its medical specialties to a growing base of patients across the U.S. We look forward to working with the IntegraMed team to support them in building upon their industry leading position and in achieving continued success.” Jay Higham, CEO and President of IntegraMed, commented, “This is an exciting day for IntegraMed, our patients, physicians and staff as we begin our new partnership with Sagard Capital. As a private company and with the full strategic and financial support of Sagard, IntegraMed is now uniquely positioned to expand the reach of the patient communities we serve. We will also be able to invest aggressively in supporting our physicians and clinic staff to improve the quality of patient care. At the same time, we will continue to explore ways to leverage the IntegraMed model into new areas of specialty and to drive further efficiency into our operations while also bringing innovation to the solutions we provide.”
Shares of IntegraMed America (Nasdaq:INMD) have taken a tremendous swing upward. The stock is trading at $13.71 as of 9:55 a.m. ET, 20.9% above Friday's closing price of $11.34. Volume is at 476,658, 22.5 times the daily average of 21,200.